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Context:Congenital leptin deficiency is a very rare cause of severe early-onset obesity.We recently
characterizedamutation in the leptingene (p.D100Y),whichwasassociatedwithdetectable leptin
levels and bioinactivity of the hormone.
Case Description:We now describe two siblings, a 9-year-old girl and a 6-year-old boy with severe
early-onset obesity and hyperphagia, both homozygous for a c.309CA substitution in the leptin
gene leading to a p.N103K amino acid exchange in the protein and detectable circulating levels of
leptin. In vitro experiments in a heterologous cell system demonstrated that the mutated protein
was biologically inactive. Treatment with sc recombinant human leptin led to rapid improvement
of eating behavior and weight loss.
Conclusions: Sequencingof the leptingenemayneed tobe considered inhyperphagic, severely obese
children with detectable levels of circulating leptin. (J Clin Endocrinol Metab 100: 3227–3230, 2015)
Congenital leptin deficiency is characterized by hy-perphagia and severe early-onset obesity, alongwith
metabolic and endocrine derangements and in some cases
also immunological alterations (1–3). The disease is
caused by mutations in the LEP gene typically leading to
defects in protein synthesis or secretion, and therefore to
the absence or very low levels of the hormone in the cir-
culation (1, 2). Recently, we described the first case of
functional leptindeficiency (4).This entity is characterized
by detectable immunoreactive levels of circulating leptin,
but bioinactivity of the hormone due to defective receptor
binding (4).Wenowdescribe twoadditional cases of func-
tional leptin deficiency due to a c.309CA substitution in
the LEP gene resulting in an asparagine to lysine amino
acid exchange at position 103 of the protein (p.N103K).
Subjects and Methods
Leptin sequencing and ELISA
All human studieswere conducted according to the principles
outlined in the Declaration of Helsinki and after approval by
local ethical committees. All individuals or their parents (for
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children) gave written informed consent. Severely obese patients
from the Genetics of Obesity Study (GOOS) cohort (5) were
sequenced for mutations in leptin gene (LEP) as reported pre-
viously (3).
Leptin concentrations were measured by ELISA using kits
fromIBL,with adetection limit of 1ng/mL, interassay coefficient
of variation (CV) of 8.7–11.6%, and intra-assay CV of 6.0–
6.9%; and from Assaypro, with a detection limit of approxi-
mately 0.12 ng/mL, interassay CV of 7.0%, and intra-assay CV
of 4.7%. Leptin concentrations in cell culture media were mea-
sured using a kit from BioVendor with a detection limit of 0.17
ng/mL, interassay CV of 7.5%, and intra-assay CV of 9.2%,
respectively.
Transfection and functional studies
Plasmid vectors encoding wild-type and p.N103K leptin and
corresponding fluorescent fusion proteins were generated as de-
scribed earlier (4). Leptin-containing cell culture supernatants
were prepared by transfection of HEK293 cells as described (4,
6). ForWestern blot analysis of leptin production and secretion,
a rabbit polyclonal antileptin antibody (BioVendor) was used.
For signaling studies, HEK293-hLR-FLAG cells transiently
overexpressing the human leptin receptor (hLR-FLAG, kindly
provided by Jan Tavernier, University of Ghent, Belgium) were
treated with leptin-containing supernatants (adjusted to 30
ng/mL leptin). Cell lysates were subjected to Western blot anal-
ysis as described (4).
For internalization studies, HEK293-hLR-FLAG cells were
treated with leptin-mCherry-containing supernatants (adjusted
to30ng/mL leptin).The cellswere fixedwithparaformaldehyde,
counterstained with Hoechst 33342 (trihydrochloride-trihy-
drate; Life Technologies), and subjected to fluorescence analysis
on an Olympus IX-70 microscope (Olympus).
Results
Case history
The patients are siblings, the second and third children
of two healthy, nonobese Caucasian (German) parents
without known consanguinity. PatientA, the second-born
girl, was delivered by cesarean section. Birth weight and
height were normal. After 4 weeks of full breastfeeding,
she became clinically conspicuous by insatiable appetite
with the introduction of bottle-feeding at the age of 5
weeks. She rapidly gained weight and developed severe
obesity (Figure 1A). Circulating levels of leptin were high
Figure 1. Bioinactivity due to a p.N103K mutation in leptin. A, Body weight curves of the patients (boy, blue line; girl, red line) and the healthy,
normal-weight sister (black line) compared to body weight percentiles for boys (blue dotted lines) and girls (red dotted lines). The triangle indicates
the start of treatment. B, Pedigree indicating the mutation status of the parents and their three children. The BMI is given in kilograms per square
meter, along with the corresponding age in years. C, HEK293 cells were transfected with empty vector (Ctrl) or vector encoding wild-type (Wt) or
p.N103K (N103K) leptin. After 48 hours, media supernatants (Sup) were collected, cell lysates (Lys) were prepared, and leptin immunoreactivity
was examined by Western blot analysis. -Actin served as a loading control. One representative experiment out of three performed is shown. D,
HEK293 cells were transfected with either empty vector (Ev) or vector encoding the human leptin receptor (hLR). Cells were treated with media
supernatants from HEK293 cells transfected with empty vector (Ctrl) or vector encoding wild-type (Wt) or p.N103K (N103K) leptin for 15 minutes.
Concentrations of wild-type and p.N103K leptin were adjusted to 30 ng/mL. Cell lysates were prepared and subjected to Western blot analysis
using pStat3 and Stat3 antibodies. -Tubulin served as a loading control. One representative experiment out of three performed is shown. E,
HEK293 cells were transfected with vector encoding the human leptin receptor. Cells were treated with media supernatants from HEK293 cells
transfected with vector encoding mCherry-labeled wild-type (Wt) or p.N103K (N103K) leptin for 45 minutes. Concentrations of wild-type and
p.N103K leptin were adjusted to 30 ng/mL. The cells were fixed, the nuclei were stained with Hoechst 33342 (Hoechst), and the cells were
analyzed by fluorescence microscopy. Blue, nuclei; red, mCherry-labeled leptin. One representative experiment out of three performed is shown.
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(50ng/mL). Intensive outpatient and inpatientmeasures
aiming at influencing eating behavior as well as the moth-
er-child interactionweremade, butwithmarginal success.
An experimental treatment trial withmethylphenidate for
13months, with amaximal dose of 60mg/d starting at the
age of 7 years, resulted in a reductionof the bodymass index
(BMI) from 35.6 to 34.8 kg/m2. Ultimately, however, none
of the interventions could influence the dramatic weight de-
velopment. Information on anthropometric, endocrine, and
metabolic parameters is summarized in Table 1.
The third-bornboydisplayed the same symptomsas the
second-born child (Table 1). Born with normal weight, he
rapidly showed marked hyperphagia and pronounced
weight gain (Figure 1A) with high levels of serum leptin
(70 ng/mL). The first-born girl showed normal weight
development (Figure 1, A and B).
On the basis of our recent description of the first case
of congenital functional leptin deficiency (4), we had the
suspicion of biological inactive leptin also in these two
siblings. Analysis of the LEP gene sequence showed a ho-
mozygous cytosine to adenine base substitution (transver-
sion) in exon 3 (c.309CA), which resulted in an aspar-
agine to lysine amino acid exchange in the protein
(p.N103K). Both parents were heterozygous carriers of
the mutation, whereas the lean sibling was homozygous
for the wild-type allele (Figure 1B). Sequencing of an ad-
ditional 290 children with severe early-onset obesity with
detectable leptin levels from theGenetics ofObesity Study
(GOOS) did not reveal additional mutations in LEP. Be-
cause this cohort included patients from consanguineous
families and with clinical features strongly suggestive of
the disorder, these findings suggest that mutations result-
ing in a bioinactive form of leptin are a very rare cause of
severe, early-onset obesity.
Secretion studies inHEK293cells overexpressing either
the wild type or the mutant leptin demonstrated that the
p.N103K variant is indeed released into the cell culture
medium (Figure 1C).However,whereas thewild-type lep-
tin was able to induce the phosphorylation of Stat3 in
HEK293 cells overexpressing the human leptin receptor,
the p.N103K mutant was unable to do so (Figure 1D).
Likewise, the mutant mCherry-tagged leptin did not bind
to or cause internalization of the leptin receptor, whereas
the wild-type hormone exerted these functions (Figure
1E). This set of experiments clearly demonstrates that
p.N103K leptin mutant is secreted, but is not functional.
As expected, treatment of both children with metreleptin
injection of 0.03 mg per kilogram of lean body weight per
day led to an improvement of hyperphagia, satiety after
consumption of normal amounts of food, and subsequent
weight loss (Figure 1A).
Discussion
This case report demonstrates that functional leptin defi-
ciency should be considered in children with uncontrol-
lable hyperphagia and rapid weight gain in early child-
hood. Although measuring serum levels of leptin is
appropriate to diagnose classical congenital leptin defi-
ciency, which is characterized by the absence or very low
levels of the hormone in the circulation, sequence analysis
of the LEP gene revealed a small subset of patients with a
bioinactive form of leptin, as described earlier for the
p.D100Y (4) and herein for the p.N103K mutant.
Table 1. Anthropometric, Endocrine, and Metabolic Characteristics of Patients Before and After the Start of
Treatment With Metreleptin
Parameter/Time of Treatment
Patient A Patient B
Day 0 Day 4 Day 9 Week 8 Day 0 Day 4 Day 9 Week 8
Age, mo 117 117 117 119 76 76 76 78
Weight, kg 77.9 78.1 76.7 71.7 50.4 51.3 50.6 46.6
BMI, kg/m2 39.6 39.7 39.0 35.8 35.2 35.8 35.3 31.7
BMI z-score 3.5 3.5 3.5 3.3 4.1 4.1 4.1 3.8
Leptin, ng/mL 59.7 56.2 46.9 64 74.6 nd 56.8 20.4
Insulin, mU/L 32.5 30.6 51.1 22.7 19.8 13.8 8.8 10.8
C-peptide, ng/mL 3.8 3.6 4.6 3 3 2.8 1.8 2.2
Triglycerides, mmol/L 1.4 1.5 1.6 1.5 0.8 1.2 0.4 0.9
ALT, U/L 20 18 21 35 16 32 41 37
AST, U/L 22 25 27 35 25 36 53 43
GGT, U/L 15 14 nd 11 17 19 nd 30
Cortisol, g/dL 4.8 5.8 5.8 16.3 8.8 8.5 9.5 5.1
IGF-1, ng/mL 134 129 133 153 41 54 54 70
IGFBP-3, ng/mL 3360 3470 3950 3590 1830 2450 2400 2560
LH, U/L 0.1 0.1 nd 0.1 0.1 0.1 nd 0.1
FSH, U/L 0.3 0.3 nd 1.05 0.6 nd nd 1.8
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GGT, -glutamyl transpeptidase; IGFBP-3, IGF binding protein 3; nd, not
determined.
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From a structural point of view, the p.N103K substi-
tutiondoesnot appear toalter theoverall structureofhelix
C of leptin. Similar to the side chains of p.D100 and
p.Y100, the side chains of p.N103 and p.K103 protrude
from helix C of leptin to the surface of the leptin binding
domain (LBD) of the human leptin receptor. At the point
of contact to leptin p.N103, the binding site on LBD is
made up of a hydrophobic IFLL cluster (amino acids 503
to 506 of the human leptin receptor, Uniprot ID: P48357–
1). The binding site on LBD can accommodate the neutral
carboxamide side chain of p.N103. The side chain of
p.K103, however, is both longer by about 2.6 Å (7) and
positively charged at physiological pH. Thus, it is likely
that the hydrophobic IFLL pocket on LBD does not ac-
commodate p.K103 as a substitute of p.N103. The
p.N103K mutation described here has already been re-
ported in two obese patients from Egypt, but it was de-
scribed to be associated with low levels of circulating lep-
tin (8). We first suspected that the ELISA kit used in that
study might have been unable to recognize the mutant
protein. This was, however, excluded by measuring pa-
tient serum and media supernatants from HEK293 cells
overexpressing the p.N103K leptin with the ELISA kit
used in the original study, which yielded concentrations
comparable to thosemeasuredwithotherkits (50ng/mL
leptin for both patients). Interestingly, the biological ac-
tivity of p.N103K leptin has been addressed earlier (9). In
line with our findings, Niv-Spector et al (9) reported a
reduced binding affinity of the mutant protein to the LBD
of the human leptin receptor. Our data provide in vivo
proof that the p.N103K mutation causes obesity due to
biological inactivity, but in thepresenceof high circulating
levels of the mutant leptin hormone. Taken together, our
study once again illustrates bioinactivity of leptin as a
cause of pharmacologically treatable, early-onset, severe
obesity.
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